Ren Ren Net Worth

What's Ren Ren's mailing address?

Ren's mailing address filed with the SEC is C/O MYOS RENS TECHNOLOGY INC., 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS, NJ, 07927.

Insiders trading at MYOS RENS Technology

Over the last 12 years, insiders at MYOS RENS Technology have traded over $0 worth of MYOS RENS Technology stock and bought 2,115,845 units worth $2,654,259 . The most active insiders traders include David J Matlin, Christopher Pechock oraz Joseph Mannello. On average, MYOS RENS Technology executives and independent directors trade stock every 78 days with the average trade being worth of $59,361. The most recent stock trade was executed by Joseph Mannello on 31 March 2020, trading 16,529 units of MYOS stock currently worth $16,694.

What does MYOS RENS Technology do?

MYOS RENS Technology, Inc. operates as a nutrition company, develops and markets products that improve muscle health and performance. Its primary product is Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk, intended to increase lean muscle mass, size, and strength. The company was founded on April 11, 2007 and is headquartered in Cedar Knolls, NJ.

MYOS RENS Technology executives and stock owners

MYOS RENS Technology executives and other stock owners filed with the SEC include:

• Joseph Mannello,
  Chief Executive Officer, Director
• Robert Hariri,
  Independent Chairman of the Board
• Eric Zaltas,
  Independent Director
• Andrew Ponte,
  Independent Director
• Christopher Pechock,
  Independent Director
• Victor Mandel,
  Independent Director
• Christopher Dewey,
  Independent Director
• Louis Aronne,
  Independent Director
• Ren Ren,
  Director
• Sapna Srivastava,
  Director
• Joseph Dos Santos,
  Chief Financial Officer
• Kenrick Bryce Toussaint,
  Chief Executive Officer
• Buzz Aldrin,
  Director
• Zhengguang Lyu,
  Director
• Robert C. Jr. Ashton,
  Chief Medical Officer
• Peter Diamandis,
  Director
• John Craig Venter,
  Director
• Peter Levy,
  COO & Executive VP
• John Nosta,
  Director
• Carl De Freitas,
  Interim CFO
• Glen R. Fleischer,
  Chief Executive Officer
• David J Matlin,
  10% owner